The invention provides an A² peptide aggregation inhibitor, an A² peptide toxicity reducing agent, and a preventive and/or therapeutic agent for Alzheimers disease. The oxidized A² peptide in which one or more amino acid residues of A² peptide have been oxidized (excluding an oxidized A² peptide in which only Met has been oxidized).